Long-term renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis of risk factors in an Asian patient population.
Wei ZhouRehena SultanaColin DiongYeow-Tee GohSathish GopalakrishnanAloysius HoWilliam HwangLiang-Piu KohMickey KohYvonne LohPatrick TanYeh-Ching LinnPublished in: Clinical transplantation (2017)
Allogeneic hemopoietic stem cell transplantation (allo-HSCT) poses a significant challenge to renal function due to multiple drug- and complication-related renal toxicity. In this single-center series of 216 adult Asian patients with a long and complete follow-up, 41 developed chronic kidney disease (CKD) giving a cumulative incidence of 19.0% at 25 years (median follow-up duration 7.84 years, range 2.0-27.7 years), but only two of the 41 patients reached stage 4 CKD and another two required dialysis. In contrast, acute kidney injury occurred in most patients, where glomerular filtration rate (GFR) suffered a mean fall of 50 mL/min/1.73 m2 at 6 months post-transplant compared with baseline. Suppression of renal function may last beyond 6 months but is potentially reversible, although not to baseline level in most patients. Analysis of a comprehensive range of 18 risk factors showed that older age, lower GFR at transplant, unrelated donor, diagnosis of AML, presence of diabetes mellitus at transplant, and duration of foscarnet use were significantly associated with CKD development, with the first three remaining as independent risks for CKD in multivariate analysis. Long-term survival is not affected by renal function, being 78.6% as compared to 85.5% for patients with low vs normal GFR at 2 years, respectively.
Keyphrases
- chronic kidney disease
- end stage renal disease
- stem cell transplantation
- risk factors
- peritoneal dialysis
- ejection fraction
- acute kidney injury
- newly diagnosed
- stem cells
- magnetic resonance
- acute myeloid leukemia
- prognostic factors
- bone marrow
- cardiac surgery
- metabolic syndrome
- computed tomography
- young adults
- acute lymphoblastic leukemia
- adipose tissue
- patient reported outcomes